#Inspiration

Aruna Subramanian is leading study for potential COVID-19 drug Remdesivir

Dr Aruna Subramanian Covid investigation

Dr Aruna Subramanian is the lead investigator in what can be a potential breakthrough drug for COVID-19. The Stanford Medicine professional is a trained doctor in infectious diseases and based out of Palo Alto in California. Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. The doctor, who has been practising for the last twenty years is a recipient of Johns Hopkins University School of Medicine Infectious Diseases Fellowship. Subramanian is the lead investigator in the phase three clinical trial of the antiviral drug Remdesivir. The Indian-American physician, noted that patients taking the drug course saw improvement from COVID conditions. Here’s why you need to know her.

  • She is the lead investigator in a trial for finding a potential drug to treat COVID 19 during the coronavirus pandemic.
  • She is from University of Michigan Honors College and Medical School, Case Western Reserve University Hospitals of Cleveland Internal Medicine Residency, Johns Hopkins University School of Medicine Infectious Diseases Fellowship
  • Her current position is Chief, Immunocompromised Host Infectious Diseases, Clinical Associate Professor, Stanford University School of Medicine
  • She is a trained South Indian classical dancer.
  • Dr Subramanian’s daughter is part of a dance troupe and does performances in South Indian classical dance.
  • She helps organize Indian dance shows around the United States.
  • She is part of the lead investigations team at Stanford Medicine along with Gilead Science, the drug company, to fetch answers to the COVID-19 virus. A breakthrough in this study was found through a large-scale clinical trial of a drug called remdesivir. “We brought this on fast,” said Aruna Subramanian, MD, clinical professor of infectious disease and co-principal investigator of the Gilead trials at Stanford. She talks of how this unusual situation around the world led them to fast track efforts. “We got everything together in a week and were ready to roll. This was record time. This type of thing normally takes two to three months to get on board.”
  • Her inspiration? In the field of medicine, she has said, “I was inspired to work in transplantation by a mentor at Johns Hopkins named Pamela Tucker.” She adds, “She [Tucker] was extremely dedicated to patient care, consulting on transplant patients all by herself, but sadly passed away when I was a senior fellow.  We decided to build a full-fledged transplant ID service in her memory.”